Literature DB >> 19141165

Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance.

S L Carpenter1, P Mathew.   

Abstract

Fibrinolysis serves an important role in the process of coagulation, ensuring that clots that are formed in response to injury resolve after the injured tissue is repaired. Fibrinolysis occurs because the protein plasminogen is converted to the active serine protease plasmin by its activating molecules (primarily tissue plasminogen activator). One of the inhibitors of fibrinolysis is alpha(2)-antiplasmin, which acts as the primary inhibitor of plasmin(ogen). Congenital deficiency of alpha(2)-antiplasmin causes a rare bleeding disorder because of increased fibrinolysis. Despite the rare nature of this disorder, understanding of the actions of alpha(2)-antiplasmin and the results of its deficiency has provided the opportunity for better understanding of the fibrinolytic system in both how it affects the risk of bleeding and its impact on other bodily systems. Here, we review the history of the discovery of alpha(2)-antiplasmin, our understanding of its genetics and function, and our current knowledge of its congenital deficiency. We also discuss some of the current avenues of investigation into its impact on other diseases and physiological states.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19141165     DOI: 10.1111/j.1365-2516.2008.01766.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  31 in total

1.  The Rheumatoid Arthritis-Associated Citrullinome.

Authors:  Ronak Tilvawala; Son Hong Nguyen; Aaron J Maurais; Venkatesh V Nemmara; Mitesh Nagar; Ari J Salinger; Sunil Nagpal; Eranthie Weerapana; Paul R Thompson
Journal:  Cell Chem Biol       Date:  2018-04-05       Impact factor: 8.116

2.  Amorphous protein aggregates stimulate plasminogen activation, leading to release of cytotoxic fragments that are clients for extracellular chaperones.

Authors:  Patrick Constantinescu; Rebecca A Brown; Amy R Wyatt; Marie Ranson; Mark R Wilson
Journal:  J Biol Chem       Date:  2017-07-14       Impact factor: 5.157

Review 3.  Trauma-Induced Coagulopathy: An Institution's 35 Year Perspective on Practice and Research.

Authors:  E Gonzalez; E E Moore; H B Moore; M P Chapman; C C Silliman; A Banerjee
Journal:  Scand J Surg       Date:  2014-04-30       Impact factor: 2.360

4.  Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites.

Authors:  Galina Tsurupa; Sergiy Yakovlev; Patrick McKee; Leonid Medved
Journal:  Biochemistry       Date:  2010-09-07       Impact factor: 3.162

Review 5.  Fibrinolysis and the control of blood coagulation.

Authors:  John C Chapin; Katherine A Hajjar
Journal:  Blood Rev       Date:  2014-09-16       Impact factor: 8.250

6.  Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin.

Authors:  K N Lee; K W Jackson; V J Christiansen; E K Dolence; P A McKee
Journal:  J Thromb Haemost       Date:  2011-05       Impact factor: 5.824

7.  Alpha 2-antiplasmin deficiency in a Sudanese child: a case report.

Authors:  Bashir Abdrhman Bashir Mohammed
Journal:  J Med Case Rep       Date:  2021-05-07

8.  Hemorrhagic Shock after Neonatal Circumcision: Severe Congenital Factor XIII Deficiency.

Authors:  Erin L Cohen; Samantha E Millikan; Perry C Morocco; Jill L O de Jong
Journal:  Case Rep Pediatr       Date:  2021-05-03

9.  28-day thawed plasma maintains α2 -antiplasmin levels and inhibits tPA-induced fibrinolysis.

Authors:  Gregory R Stettler; Ernest E Moore; Benjamin R Huebner; Geoffrey R Nunns; Hunter B Moore; Julia R Coleman; Marguerite Kelher; Anirban Banerjee; Christopher C Silliman
Journal:  Vox Sang       Date:  2020-09-07       Impact factor: 2.144

10.  The role of SERPIN citrullination in thrombosis.

Authors:  Ronak Tilvawala; Venkatesh V Nemmara; Archie C Reyes; Nicoletta Sorvillo; Ari J Salinger; Deya Cherpokova; Saeko Fukui; Sarah Gutch; Denisa Wagner; Paul R Thompson
Journal:  Cell Chem Biol       Date:  2021-08-04       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.